Adverum Biotech Reports Encouraging Initial Results for Safety and Effectiveness in Phase 2 LUNA Study of Ixo-vec for Wet Age-Related Macular Degeneration Patients.
In a Phase 2b clinical trial, the experimental oral peptide known as JNJ-2113 has shown encouraging outcomes for patients with moderate to severe psoriasis.
Encoded Therapeutics Reveals Approval from US FDA for IND Application and Consent from Australian Health Authorities for ETX101, a Genetic Treatment Prospect for Dravet Syndrome.
Johnson & Johnson has announced encouraging initial findings from a critical Phase 3 trial with nipocalimab for treating generalized myasthenia gravis, as well as from a Phase 2 investigation in Sjögren's Disease.